OXiGENE reports positive interim results from Phase II cancer trial
The company said that 10 of 34 evaluable patients (29%) enrolled to date in the ongoing, single-arm, Simon two-stage design study evaluating the combination of Zybrestat and chemotherapy
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.